Development of a deregulating MicroRNA panel for the detection of early relapse in postoperative colorectal cancer patients

Wang, J.Y.; Yang, I‐Ping

doi:10.1016/s0959-8049(16)61637-4

Cited by 6 publications

(6 citation statements)

References 48 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tang et al (2015) found that in comparison with expression in the normal colorectal mucosa, miR‐93‐5p expression was lower in human CRC tissues and cell lines. Moreover, the low expression of miR‐93 was reported to be relevant to advanced tumor stage, positive nodal metastasis, and positive distant metastases in human colon cancer (Gallaher et al, 2013), indicating its relation to poor survival (Yang et al, 2016), which was all in agreement with our findings. Thus, miR‐93‐5p may serve as a therapeutic target to regulate the progression and prognosis of CRC by targeting PD‐L1 .…”

Section: Discussionsupporting

confidence: 92%

“…On the basis of the prediction of multiple online databases, we also found that PD‐L1 is a target gene of miR‐93‐5p, which is a member of the miR‐106b‐25 gene cluster that is abnormally expressed in various tumor tissues (Garbicz et al, 2017; Xiang et al, 2017). Previous evidence has identified the downregulation of miR‐93‐5p in CRC, suggesting the potential tumor‐suppressive role of miR‐93‐5p (Xiao et al, 2013; Yang et al, 2016). Additionally, Cioffi et al (2017) reported that miR‐93 suppresses the immune evasion and metastasis of pancreatic cancer via targeting PD‐L1 , but the specific effect in CRC remains unclear.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer

Chen

Wang

Lin

et al. 2020

Cell Biology International

View full text Add to dashboard Cite

This work aimed to investigate miR-93-5p expression in tumor tissue and its in vitro effects in colorectal cancer (CRC) by targeting programmed death ligand-1 (PD-L1). MiR-93-5p and PD-L1 expression was detected in CRC and adjacent normal tissues by quantitative real-time polymerase chain reaction and immunohistochemistry. The correlation between miR-93-5p and PD-L1 was validated by a dual-luciferase reporter assay. HCT116 and SW480 cells were divided into blank, miR-NC, miR-93-5p mimics, miR-93-5p inhibitor, PD-L1 small interfering RNA (siRNA) and miR-93-5p inhibitor + PD-L1 siRNA groups, and wound-healing and transwell assays were performed to detect cell migration and invasion, respectively. Protein expression was measured by western blotting. The secretion of cytokines was detected in the CRC cell/T coculture models. MiR-93-5p was downregulated in CRC tissues with upregulated PD-L1. In PD-L1-negative patients, miR-93-5p expression was increased compared with that in PD-L1-positive patients. MiR-93-5p and PD-L1 expression levels were associated with the tumor differentiation, lymphatic metastasis, TNM, Duke's stage, and prognosis of CRC. PD-L1 siRNA weakened the migration and invasion abilities via decreased expression of matrix metalloproteinase-1 (MMP-1), -2, and -9, and these effects were abolished by the miR-93-5p inhibitor. Additionally, anti-PD-L1 upregulated the expressions of interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), and interferon γ (IFN-γ) in the coculture of T cells with CRC cells, but downregulated the expressions of IL-1β, IL-10, and TGF-β. However, these changes were partially reversed by miR-93-5p inhibition. miR-93-5p is expected to be a novel target for CRC treatment since it decreases the migration and invasion, as well as the immune evasion, of CRC cells via targeting PD-L1. Abbreviations: CRC, colorectal cancer; ELISA, enzyme-linked immunosorbent assay; HE, hematoxylin and eosin; ITIM, immunoreceptor tyrosinebased inhibitory motif; miRNA, microRNA; PD-L1, programmed death ligand-1 Role of miR-93-5p in CRC via targeting PD-L1Y.-L. Chen et al.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 95%

MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer

Chen

Wang

Lin

et al. 2020

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…Chen et al demonstrated that miR‐93 was a potential suppressor of ovarian cancer by inhibiting ras homolog gene family member C (RhoC) expression. The role of miR‐93 as a tumor suppressor in colorectal cancer has also been reported . It was indicated that miR‐93 could suppress proliferation and colony formation of human colon cancer stem cells .…”

Section: Introductionmentioning

confidence: 95%

Molecular mechanism and role of microRNA‐93 in human cancers: A study based on bioinformatics analysis, meta‐analysis, and quantitative polymerase chain reaction validation

Gao

Deng

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Introduction Currently, studies have shown that microRNA‐93 (miR‐93) can be an oncogene or a tumor suppressor in different kinds of cancers. The role of miR‐93 in human cancers is inconsistent and the underlying mechanism on the aberrant expression of miR‐93 is complicated. Methods We first conducted gene enrichment analysis to give insight into the prospective mechanism of miR‐93. Second, we performed a meta‐analysis to evaluate the clinical value of miR‐93. Finally, a validation test based on quantitative polymerase chain reaction (qPCR) was performed to further investigate the role of miR‐93 in pan‐cancer. Results Gene Ontology (GO) enrichment analysis results showed that the target genes of miR‐93 were closely related to transcription, and MAPK1, RBBP7 and Smad7 became the hub genes. In the diagnostic meta‐analysis, the overall sensitivity, specificity, and area under the curve were 0.76 (0.64‐0.85), 0.82 (0.64‐0.92), and 0.85 (0.82‐0.88), respectively, which suggested that miR‐93 had excellent performance on the diagnosis for human cancers. In the prognostic meta‐analysis, dysregulated miR‐93 was found to be associated with poor OS in cancer patients. In the qPCR validation test, the serum levels of miR‐93 were upregulated in breast cancer, breast hyperplasia, lung cancer, chronic obstructive pulmonary disease, nasopharyngeal cancer, hepatocellular cancer, gastric ulcer, endometrial cancer, esophageal cancer, laryngeal cancer, and prostate cancer compared with healthy controls. Conclusions miR‐93 could act as an effective diagnostic and prognostic factor for cancer patients. Its clinical value for cancer early diagnosis and survival prediction is promising.

show abstract

“…Mounting efforts have been devoted to discover protein-based, DNA-based, RNA-based, or circulating tumor cell-based screening tests, and miRNA is one of the most promising molecular biomarkers for tumor early diagnosis and prediction of prognosis (6). miRNAs, a class of small noncoding RNA molecules, are common 19-25 nucleotides in length.…”

Section: Introductionmentioning

confidence: 99%

Circulating Exosomal miR-27a and miR-130a Act as Novel Diagnostic and Prognostic Biomarkers of Colorectal Cancer

Liu

Pan

Sun

et al. 2018

Cancer Epidemiology, Biomarkers &Amp; Prevention

100

View full text Add to dashboard Cite

Colorectal cancer is one of the most common cancers worldwide usually is associated with poor prognosis due to the advanced stage when diagnosed. This study aimed to investigate whether specific circulating exosomal miRNAs could act as biomarkers for early diagnosis of colorectal cancer. A total of 369 peripheral blood samples were included in this study. In the discovery phase, circulating exosomal miR-27a and miR-130a were selected after synthetical analysis of two GEO datasets and TCGA database. The differential expression and diagnostic utility of miR-27a and miR-130a panel were validated using qRT-PCR and ROC curve analysis in subsequent training phase, validation phase, and external validation phase. The prognosis of circulating exosomal miR-27a and miR-130a were investigated using the Kaplan-Meier method. The expression of exosomal miR-27a and miR-130a in plasma significantly increased in colorectal cancer. The area under ROC curves (AUC) of miR-27a (miR-130a) were 0.773 (0.742) in the training phase, 0.82 (0.787) in the validation phase, and 0.746 (0.697) in the external validation phase. The combination of two miRNAs presented higher diagnostic utility for colorectal cancer (AUCs = 0.846, 0.898, and 0.801 for the training, validation, and external validation phases, respectively). Patients with colorectal cancer with high expression of circulating exosomal miR-27a or miR-130a underwent poorer prognosis. We identified a circulating exosomal miRNAs panel for the detection of colorectal cancer. The exosomal miR-27a and miR-130a panel in plasma may act as a noninvasive biomarker for early detection and predicting prognosis of colorectal cancer. .

show abstract

Development of a deregulating MicroRNA panel for the detection of early relapse in postoperative colorectal cancer patients

Cited by 6 publications

References 48 publications

MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer

MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer

Molecular mechanism and role of microRNA‐93 in human cancers: A study based on bioinformatics analysis, meta‐analysis, and quantitative polymerase chain reaction validation

Circulating Exosomal miR-27a and miR-130a Act as Novel Diagnostic and Prognostic Biomarkers of Colorectal Cancer

Contact Info

Product

Resources

About